Use Of Heterocyclic Carbaldehyde Derivatives Against Sickle Cell Anemia

  • Published: Apr 28, 2010
  • Earliest Priority: Dec 04 2002
  • Family: 19
  • Cited Works: 44
  • Cited by: 2
  • Cites: 3
  • Additional Info: Cited Works Published
Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The invention provides compounds for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and nontoxic, and methods for their use. The compounds include analogues and derivatives of naturally occurring 5-hydroxymethyl-2-furfuraldehyde, 5-Ethyl-2-furfuraldehyde, 5-Methyl-2furfuraldehyde, and 2-furfuraldehyde, and prodrug forms of the compound.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Apr 28, 2010
  • Application: Dec 3, 2003
    EP EP 10152353 A
  • Priority: Dec 3, 2003
    EP EP 03787240 A
  • Priority: Oct 20, 2003
    US US 51218703 P
  • Priority: Oct 17, 2003
    US US 51167103 P
  • Priority: Dec 4, 2002
    US US 43068102 P

Download Citation


Sign in to the Lens

Feedback